Ependymoma

Ependymomas occur in children and adults. Brain tumors may obstruct cerebrospinal fluid flow and cause headaches, vomiting or balance problems. Spinal tumors can cause back pain, weakness, numbness and bladder or bowel changes. New weakness, loss of bladder control or rapidly worsening alertness needs urgent evaluation.

Spread outside the central nervous system is unusual, but tumor can travel within it through cerebrospinal fluid. The team therefore considers the entire brain and spine, not just the site causing symptoms.

Modern classification combines pathology with anatomical location and molecular findings. An older report saying only “anaplastic ependymoma” may need an integrated update before a major treatment decision.

Grade is not a stage from I to IV. Histology alone does not capture every risk difference; the diagnosis, extent of removal, spread and age must be considered together. MYCN-amplified spinal disease can behave much more aggressively than a typical spinal tumor.

Contrast-enhanced MRI maps the tumor and its relationship to the brainstem, nerves or spinal cord. Brain and spine imaging and, when appropriate and safe, cerebrospinal fluid testing assess dissemination. Postoperative MRI helps distinguish complete removal from residual disease.

Maximum safe resection is important, but preserving swallowing, movement, sensation and other essential functions matters too. For an accessible remnant, expert review may identify a useful second operation. A reoperation should have a clear expected benefit rather than pursue complete removal at any cost.

Many children with a newly diagnosed intracranial ependymoma receive focal radiotherapy after surgery, including some with no visible residual tumor. The target is usually the involved region, rather than routine whole-brain and whole-spine treatment. Disseminated disease requires a separate plan.

Selected completely resected supratentorial grade 2 tumors have been managed with observation in COG studies. This is a specific expert-reviewed pathway, not evidence that all completely removed or favorable-molecular tumors can omit radiation.

Young age calls for careful planning, not a blanket rule that every child under three must avoid radiation. Infants, especially under one year, may need chemotherapy to defer irradiation or facilitate further surgery. Modern photon and proton plans should be compared for tumor coverage and protection of developing tissues.

The phase 3 ACNS0831 trial studied children and young people aged 1–21 with newly diagnosed intracranial ependymoma. Among patients eligible for randomization after the surgical/induction pathway, adding maintenance chemotherapy after radiotherapy did not demonstrate a significant benefit in the primary analysis.

This argues against routinely adding that chemotherapy program simply because radiotherapy has finished. It does not prove that all chemotherapy is useless: treatment before a second operation, management of very young children and salvage treatment at recurrence are different questions. Longer follow-up is still relevant because late relapses occur.

After complete removal of a conventional grade 2 spinal tumor, observation may be appropriate. Residual or higher-grade disease more often raises the question of radiotherapy. An adult brain tumor also needs a location-specific assessment; the childhood treatment pathway is not automatically the right one.

For myxopapillary ependymoma, clarify whether removal was complete, whether the capsule was disrupted and whether there is dissemination. Its updated grade 2 classification does not mean everyone needs the same postoperative treatment, but “grade 1 and harmless” is an outdated description.

Subependymoma is a separate, usually slow-growing entity. Small incidental asymptomatic lesions may be monitored, while growth or obstruction can make surgery necessary. Spinal ependymoma can also occur with NF2-related schwannomatosis; suggestive personal or family findings warrant genetic assessment.

A recurrence should prompt review of pathology, the full neuraxis and every previous radiation plan. Repeat surgery and reirradiation can provide useful control for selected patients. Reirradiation is possible in some people who have already received radiation, but cumulative brainstem, cord and other tissue risks need careful assessment.

Recent cohorts disagree on whether craniospinal reirradiation is better than focal retreatment for an isolated local recurrence. A long-term series published in 2026 found no clear advantage for craniospinal treatment in local failures and documented serious late toxicity. This is a selection and planning question, not a reason to prescribe the widest field to everyone.

When local treatments are unsuitable or exhausted, systemic treatment or a clinical trial can be discussed. A 50-patient adult phase 2 study of temozolomide plus lapatinib reported 8 objective responses and a median progression-free interval of 7.8 months. It was not randomized and does not establish a standard first-line treatment for children or guarantee benefit in every molecular type.

Follow-up continues beyond the first few normal scans because relapse can occur years later. The team should specify brain and spine MRI coverage and frequency, what changes to report between visits, and who coordinates care when a child moves to adult services.

Rehabilitation depends on the affected structures: swallowing and speech support after posterior fossa treatment; mobility, neuropathic pain and bladder/bowel rehabilitation after spinal disease. Fatigue, sleep and emotional distress deserve attention even when scans are stable.

For children, track learning, hearing, growth and hormone function according to tumor location and treatment exposure. Discuss school accommodations early rather than waiting for a major academic decline.

Bring the material that shows both tumor biology and what has already been treated:

• Integrated pathology and molecular reports, with tissue available for review if requested.
• Brain and spine MRI before and after surgery; cerebrospinal fluid results if obtained.
• Operative report describing residual disease and capsule integrity for myxopapillary tumors.
• Radiation plans and dose files, chemotherapy history and current swallowing, walking or bladder concerns.

Ask what the integrated subtype changes, whether a remnant can be safely resected, what radiotherapy is intended to achieve and how the plan protects function. For a proposed drug or trial, confirm its evidence in this exact disease setting.